“…Calcitonin gene‐related peptide (CGRP) is a promising target to treat migraine, which has a crucial role in migraine pathophysiology. And CGRP antagonisms and CGRP monoclonal antibody (mAb) are the drugs to inhibit the CGRP pathway resulting in the migraine treatment (Deen et al, ; Deneris, Rosati Allen, Hart Hayes, & Latendresse, ; Messlinger, ; Negro, Lionetto, Simmaco, & Martelletti, ; Schuster & Rapoport, ; Yuan, Lauritsen, & Kaiser, ). Some of CGRP antagonisms related clinical trials are discontinued because of the liver injury after repeated administrations (Hong & Liu, ; Hong, Wu, & Liu, ).…”